India Pharma Outlook Team | Thursday, 16 October 2025
Marksans Pharma Limited, a major global pharmaceutical company based in Mumbai, has revealed a significant regulatory achievement for its UK operations.
Its 100% owned subsidiary, Relonchem Limited, has obtained the Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for two Clonidine products: Clonidine Tablets 100 microgram and Clonidine Hydrochloride Tablets 25 microgram.
Clonidine is a key therapeutic agent with multiple medical applications and is generally used to treat high blood pressure. The MHRA clearance allows Marksans Pharma to broaden its product range in the UK thus giving the company the capacity to meet the increased demand in the European pharmaceutical market.
Such an approval is a testament to the company’s dedication of supplying high-quality and affordable medicines to the global markets. It consolidates the position in the UK and is in line with their strategic goal of further penetrating the European market.”
Also Read: Syngene Unveils Upgraded Labs to Speed Drug Discovery
Marksans Pharma has production sites in India, the USA, and the UK, which are quite reputable as they have been approved by significant regulatory authorities such as the USFDA, MHRA, and TGA, Australia. The company’s commitment to quality, compliance, and regulatory diligence, is well exemplified by these certifications.
The approval for the marketing of Clonidine is a bold move that will lead to the expansion of the UK pharmaceutical sector. The first step for a successful market-entry would be to secure such a license, hence the present announcement will help the UK need to remember they are a great challenge to this segment.
